Covid-19 and rheumatic diseases

Basit Öğe Kaydı
dc.authorscopusid55542843700
dc.authorscopusid8944423400
dc.contributor.authorKimyon, Gezmiş
dc.contributor.authorDuman, Taşkın
dc.date.accessioned2024-09-19T15:43:35Z
dc.date.available2024-09-19T15:43:35Z
dc.date.issued2020
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an infectious agent affecting respiratory system the most and spreads rapidly due to large number of ACE2 receptors in the lung. Arthralgia and myalgia are the most common rheumatologic findings, but arthritis is rare. Hyperinflammatory condition called cytokine storm causes acute respiratory distress syndrome (ARDS) leading to death. Although coronavirus disease 2019 (COVID-19) is mild or asymptomatic in most cases, it may progress to pneumonia and ARDS, especially in elderly patients who have comorbidities. Drugs such as tocilizumab which suppress inflammatory response and reduce cytokine storm may be effective on treating COVID-19 pneumonia. Cytokine storm, the cause of which is not fully understood and in which many structures of immune system interact with each other, is quite complex and has different mechanisms contributing to it. Although antimalarial drugs such as hydroxychloroquine are used in the treatment, there is no definite evidence that they are effective. It has been shown that the prevalence and course of COVID-19 in rheumatic diseases is similar to the general population, and that increasing age and additional comorbid conditions increase the risk of mortality. It is recommended that anti-rheumatic drugs used in the treatment of rheumatic diseases should not be stopped unless the patient is infected with COVID-19. © 2020, Duzce University Medical School. All rights reserved.en_US
dc.identifier.doi10.18678/dtfd.788147
dc.identifier.endpage18en_US
dc.identifier.issn1307-671X
dc.identifier.issueSpecial Issue 1en_US
dc.identifier.scopus2-s2.0-85097164682en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage14en_US
dc.identifier.urihttps://doi.org/10.18678/dtfd.788147
dc.identifier.urihttps://hdl.handle.net/20.500.12483/14433
dc.identifier.volume22en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherDuzce University Medical Schoolen_US
dc.relation.ispartofDuzce Medical Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAnti-rheumatic drugsen_US
dc.subjectCOVID-19en_US
dc.subjectCytokine stormen_US
dc.subjectRheumatic diseasesen_US
dc.titleCovid-19 and rheumatic diseasesen_US
dc.title.alternativeCovid-19 ve romatizmal hastalıklaren_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Tam Metin / Full Text
Boyut:
360.01 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu